Anti Amyloid Kisunla denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for anti amyloid kisunla are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Kisunla as Duplicate Therapy

Kisunla (donanemab) is an FDA-approved anti-amyloid monoclonal antibody for early symptomatic Alzheimer's disease. A "duplicate therapy" denial from Humana typically occurs when the plan's system identifies that the patient has a current or recent authorization for another anti-amyloid agent — most commonly lecanemab (Leqembi) — or when both drugs appear in the patient's claim history within a short period. Humana's position is that simultaneous or closely sequential use of two agents in the same drug class is not supported and constitutes unnecessary duplication.

## Why This Denial Is Appealable

The two FDA-approved anti-amyloid agents have distinct molecular structures, dosing schedules, and clinical profiles. If the patient is transitioning from one agent to another for a documented clinical reason — such as tolerability, practical administration differences, or physician clinical judgment — that is not duplication; that is a treatment change. The appeal should clearly establish the clinical rationale for the transition and confirm that the patient is not receiving both agents simultaneously.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): A duplicate therapy denial is an adverse benefit determination. You have the right to a full-and-fair internal review. Non-urgent cases: plan must respond within 60 days. Urgent cases: 72 hours.
• External review: If the internal appeal is denied, independent external review is available under ACA §2719. File within approximately four months of the final internal denial. The external reviewer determines whether Humana's clinical criteria were applied reasonably.
• Expedited review: Available if waiting would seriously jeopardize health or ability to regain maximum function.

## Documentation to Gather

1. Current medication list and administration records — confirming whether the patient is or is not currently receiving another anti-amyloid agent, with dates. 2. Transition rationale — if switching from another anti-amyloid agent, the prescriber's documented clinical reason for discontinuing the prior agent and initiating Kisunla. 3. Diagnosis and eligibility confirmation — neurologist notes confirming early symptomatic Alzheimer's disease, amyloid confirmation method (PET or CSF), and cognitive staging consistent with the FDA-approved indication. 4. Prescriber medical-necessity letter — from the treating neurologist or dementia specialist explicitly addressing the duplicate therapy concern, confirming the patient is not receiving concurrent anti-amyloid treatment, and explaining the clinical basis for choosing Kisunla. 5. Humana's duplicate therapy policy — obtain the relevant coverage policy, identify the definition of "duplicate" used, and confirm the patient's situation does not meet that definition.

## Criteria-Mapping Structure

Address the duplicate therapy allegation directly in the first paragraph of your appeal: state plainly whether the patient is or is not simultaneously receiving another anti-amyloid agent. Attach medication records and administration logs as Exhibit A. Then provide the prescriber's clinical rationale for Kisunla as a separate, numbered section. Keep the structure crisp — this denial type often resolves quickly when the clinical facts clearly contradict the "duplicate" characterization.